At a Financial Times Future of AI Summit, Huang cited that new AI rules by 50 states could result in “50 new regulations.” Huang’s concerns about China surpassing the U.S. in the AI race is not old ...

S&P forecasts ACCO’s full-year net sales will decline about 8% in fiscal 2025, with sales declines moderating to approximately 4% in 2026. This potential improvement is expected to be driven by better ...

The rideshare sector continues to evolve in 2025, with companies expanding beyond their core transportation services. According to recent rankings from WarrenAI using Investing Pro metrics, several ...

The rating agency expects Beazer’s adjusted leverage to remain above the downgrade threshold at fiscal year-end 2025, with improvement toward 5x-6x projected for fiscal 2026. This provides the ...

Speaking at the BCVC Summit 2025 in New York, Miran explained that "even relatively conservative estimates of stablecoin ...

Investing.com -- Fitch Ratings has affirmed the Dominican Republic’s Long-Term Foreign-Currency Issuer Default Rating at ’BB-’ with a Positive Outlook.

Investing.com -- S&P Global Ratings has revised its outlook for CenterPoint Energy Inc. to stable from negative, while ...

Investing.com -- Volkswagen, Europe’s biggest carmaker, has received its first deliveries of chips from Chinese-owned ...

In a memo sent to employees on Friday, Disney Entertainment Co-Chairs Dana Walden and Alan Bergman, along with ESPN Chairman Jimmy Pitaro, stated that "YouTube TV continues to insist on receiving ...

Meta Platforms announced Friday it will invest $600 billion in U.S. infrastructure and jobs over the next three years, focusing on artificial intelligence data ce ...

Investing.com -- U.S. President Donald Trump indicated Friday that his administration is considering a potential exemption for Hungary from sanctions on Russian oil, citing the country’s heavy ...

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock dropped 3% Friday after the company announced its cancer drug Trodelvy failed to meet its primary endpoint in a Phase 3 trial for ...